; (II) developing influenza vaccines with potential universal vaccination capability; (III) developing enhanced influenza vaccines with longer lasting broad spectrum protective immunity against a wider range of antigenically divergent influenza strains; (IV) developing alternative vaccine delivery approaches; (V) developing novel small- and large-molecule novel influenza antivirals, monoclonal antibodies, and other products that provide better influenza treatment and prevention; (VI) developing innovative technologies to enhance rapid diagnosis of influenza; and (VII) implementing the National Influenza Vaccine Modernization Strategy, issued in June 2020, or any successor strategy; (ii) ensures readiness to respond to qualified pandemic and epidemic threats, including by— (I) supporting development and manufacturing of influenza virus seeds, clinical trial lots, and stockpiles of novel influenza strains; (II) supporting the stockpile of influenza antivirals through diversifying and replenishing the existing stockpile of influenza antivirals; (III) supporting manufacturing and fill-finish rapid response infrastructure; (IV) supporting the stockpile of influenza testing equipment and supplies; and (V) testing and evaluating pandemic threat rapid response capabilities through regular preparedness drills with key public and private sector partners that examine the range of activities (including production and clinical testing of influenza diagnostics, vaccines, and therapeutics) required to effectively respond to novel threats; and (iii) builds, sustains, and replenishes qualified pandemic and epidemic stockpiles of bulk antigen and adjuvant material, including by— (I) annually testing the potency and shelflife potential of all existing pandemic and epidemic stockpiles held by the Department of Health and Human Services